Bone Tumors in Adolescents and Young Adults

被引:133
作者
Bielack, Stefan S. [1 ]
Carrle, Dorothe [1 ]
Hardes, Jendrik [1 ]
Schuck, Andreas [1 ]
Paulussen, Michael [1 ]
机构
[1] Olgahospital, Klinikum Stuttgart, Klin Kinder & Jugendmed, D-70176 Stuttgart, Germany
基金
英国医学研究理事会;
关键词
D O I
10.1007/s11864-008-0057-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Bone tumors, particularly osteosarcomas and members of the Ewing Sarcoma Family of Tumors (ESFT), are typical malignancies of adolescents and young adults. Current diagnostic and therapeutic guidelines for patients of all ages were developed in this specific age group. The aim of bone sarcoma therapy should be to cure the patient from both the primary tumor and all (micro-)metastatic deposits while maintaining as much ( extremity) function and causing as few treatment-specific late effects as possible. Bone sarcoma therapy requires close multidisciplinary cooperation. Usually, it consists of induction chemotherapy, followed by local therapy of the primary tumor ( and, if present, primary metastases) and further, adjuvant chemotherapy. Local treatment for osteosarcoma should be surgery whenever feasible. Surgery is also gaining importance in ESFT, which was long considered a domain of radiotherapy. Modern reconstructive techniques continue to expand the indications for limb salvage, particularly for patients who have not yet reached skeletal maturity. Treatment within the framework of prospective, multi-institutional trials should be considered standard of care not only for children, but also for affected adolescents and ( young) adults. Such trials are essential in guaranteeing that all patients have access to appropriate care and that progress from biological studies can be translated into prognostic improvements without undue delay. The rarity of bone sarcomas increasingly requires trials to be multinational.
引用
收藏
页码:67 / 80
页数:14
相关论文
共 72 条
[1]
The use of prostheses in skeletally immature patients [J].
Abudu, A ;
Grimer, R ;
Tillman, R ;
Carter, S .
ORTHOPEDIC CLINICS OF NORTH AMERICA, 2006, 37 (01) :75-+
[2]
Samarium lexidronam (153Sm-EDTMP):: skeletal radiation for osteoblastic bone metastases and osteosarcoma [J].
Anderson, Pete ;
Nunez, Rodolfo .
EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (11) :1517-1527
[3]
Methotrexate pharmacokinetics and survival in osteosarcoma [J].
Aquerreta, I ;
Aldaz, A ;
Giráldez, J ;
Sierrasesúmaga, L .
PEDIATRIC BLOOD & CANCER, 2004, 42 (01) :52-58
[4]
Bacci G, 2004, ONCOL REP, V11, P111
[5]
The role of surgical margins in treatment of Ewing's sarcoma family tumors: Experience of a single institution with 512 patients treated with adjuvant and neoadjuvant chemotherapy [J].
Bacci, G ;
Longhi, A ;
Briccoli, A ;
Bertoni, F ;
Versari, M ;
Picci, P .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 65 (03) :766-772
[6]
Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol [J].
Bacci, G ;
Briccoli, A ;
Ferrari, S ;
Longhi, A ;
Mercuri, M ;
Capanna, R ;
Donati, D ;
Lari, S ;
Forni, C ;
DePaolis, M .
EUROPEAN JOURNAL OF CANCER, 2001, 37 (16) :2030-2039
[7]
The bioexpandable prosthesis: A new perspective after resection of malignant bone tumors in children [J].
Baumgart, R ;
Hinterwimmer, S ;
Krammer, M ;
Muensterer, O ;
Mutschler, W .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2005, 27 (08) :452-455
[8]
Prognostic factors in high-grade osteosarcoma of the extremities or trunk:: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols [J].
Bielack, SS ;
Kempf-Bielack, B ;
Delling, G ;
Exner, GU ;
Flege, S ;
Helmke, K ;
Kotz, R ;
Salzer-Kuntschik, M ;
Werner, M ;
Winkelmann, W ;
Zoubek, A ;
Jürgens, H ;
Winkler, K .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (03) :776-790
[9]
Delaying surgery with chemotherapy for osteosarcoma of the extremities [J].
Bielack, SS ;
Machatschek, JN ;
Flege, S ;
Jürgens, H .
EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (06) :1243-1256
[10]
National survival trends of young adults with sarcoma - Lack of progress is associated with lack of clinical trial participation [J].
Bleyer, A ;
Montello, M ;
Budd, T ;
Saxman, S .
CANCER, 2005, 103 (09) :1891-1897